6-methoxy-2-(4-methyl-2-propyl-imidazol-1-yl)-3-nitropyridine | 959706-54-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 6-methoxy-2-(4-methyl-2-propyl-imidazol-1-yl)-3-nitropyridine
• 英文别名: 6-Methoxy-2-(4-methyl-2-propyl-imidazol-1-yl)-3-nitro-pyridine；6-methoxy-2-(4-methyl-2-propylimidazol-1-yl)-3-nitropyridine
• CAS: 959706-54-8
• 化学式: C₁₃H₁₆N₄O₃
• 分子量: 276.295
• InChiKey: JIQWCSIIXVBYLY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  85.8
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  6-methoxy-2-(4-methyl-2-propyl-imidazol-1-yl)-3-nitropyridine 在 palladium on activated charcoal 氨 、 氢气 、 三氯氧磷 作用下， 以 乙醇 、 水 、 溶剂黄146 为溶剂， 40.0~160.0 ℃ 、1.5 MPa 条件下， 反应 24.0h， 生成 4-amino-8-methoxy-3-methyl-1-propyl-imidazo[1,5-a]pyrido[3,2-e]pyrazine
  参考文献：
  名称：

  WO2007/137820

  摘要：

  公开号：
• 作为产物：
  描述：

  2-氯-6-甲氧基-3-硝基吡啶 、 4-甲基-2-丙基-1H-咪唑 在 potassium hydroxide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 6-methoxy-2-(4-methyl-2-propyl-imidazol-1-yl)-3-nitropyridine
  参考文献：
  名称：

  Triazine derivatives as inhibitors of phosphodiesterases

  摘要：

  该发明涉及式（I）的三嗪衍生物，它们是磷酸二酯酶2或10的抑制剂，可用于治疗中枢神经系统疾病，如精神病，并且还可用于治疗例如肥胖症、2型糖尿病、代谢综合征、葡萄糖耐受不良和疼痛。

  公开号：

  US20100120762A1

文献信息

• Methods of Treating Obesity and Metabolic Disorders
  申请人：Hofgen Norbert

  公开号：US20090143392A1

  公开（公告）日：2009-06-04

  The invention relates to methods of treating or preventing obesity, type 2 diabetes, metabolic syndrome, or glucose intolerance using pyrido[3,2-e]pyrazines which are inhibitors of PDE10. The invention further relates to methods of reducing body fat or body weight.

  本发明涉及使用PDE10抑制剂pyrido [3,2-e] pyrazines治疗或预防肥胖症、2型糖尿病、代谢综合征或葡萄糖不耐症的方法。本发明还涉及减少体脂肪或体重的方法。
• Pyrido[3,2-e]pyrazines, their use as inhibitors of phospohodiesterase 10, and processes for preparing them
  申请人：Hofgen Norbert

  公开号：US20090239874A1

  公开（公告）日：2009-09-24

  The invention relates to pyrido[3,2-e]pyrazines, to processes for preparing them, to pharmaceutical preparations which comprise these compounds and to the pharmaceutical use of these compounds, which are inhibitors of phosphodiesterase 10, as active compounds for treating diseases of mammals including a human which can be influenced by using the compounds according to the invention to inhibit phosphodiesterase 10 activity in the central nervous system. More particularly, the invention relates to the treatment of neurologic and psychiatric disorders, for example psychosis and disorders comprising cognitive deficits as symptoms.

  本发明涉及吡啶并[3,2-e]吡嗪、其制备方法、含有该化合物的制药组合物以及将其作为磷酸二酯酶10的抑制剂的活性化合物，用于治疗哺乳动物包括人类的疾病，这些疾病可以通过使用本发明的化合物来抑制中枢神经系统中的磷酸二酯酶10活性来影响。具体而言，本发明涉及神经逻辑和精神障碍的治疗，例如精神病和包括认知缺陷症状的障碍。
• Pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
  申请人：Hofgen Norbert

  公开号：US20080027064A1

  公开（公告）日：2008-01-31

  The invention relates to pyrido[3,2-e]pyrazines, to processes for preparing them, to pharmaceutical preparations which comprise these compounds and to the pharmaceutical use of these compounds, which are inhibitors of phosphodiesterase 10, as active compounds for treating diseases of mammals including a human which can be influenced by using the compounds according to the invention to inhibit phosphodiesterase 10 activity in the central nervous system. More particularly, the invention relates to the treatment of neurologic and psychiatric disorders, for example psychosis and disorders comprising cognitive deficits as symptoms.

  本发明涉及吡啶并[3,2-e]吡嗪类化合物、其制备方法、包含这些化合物的制药组合物以及这些化合物的制药用途。该化合物是磷酸二酯酶10的抑制剂，可用作治疗哺乳动物包括人类的疾病的活性成分，这些疾病可以通过使用本发明的化合物抑制中枢神经系统中的磷酸二酯酶10活性来影响。具体而言，本发明涉及治疗神经和精神障碍，例如包括认知缺陷症状的精神病和障碍的治疗。
• Discovery of Imidazo[1,5-<i>a</i>]pyrido[3,2-<i>e</i>]pyrazines as a New Class of Phosphodiesterase 10A Inhibitiors
  作者：Norbert Höfgen、Hans Stange、Rudolf Schindler、Hans-Joachim Lankau、Christian Grunwald、Barbara Langen、Ute Egerland、Peter Tremmel、Menelas N. Pangalos、Karen L. Marquis、Thorsten Hage、Boyd L. Harrison、Michael S. Malamas、Nicholas J. Brandon、Thomas Kronbach

  DOI：10.1021/jm1002793

  日期：2010.6.10

  Novel imidazo[1,5-a]pyrido[3,2-e]pyrazines have been synthesized and characterized as both potent and selective phosphodiesterase 10A (PDE10A) inhibitors. For in vitro characterization, inhibition of PDE10A mediated cAMP hydrolysis was used and a QSAR model was established to analyze substitution effects. The outcome of this analysis was complemented by the crystal structure of PDE10A in complex with compound 49. Qualitatively new interactions between inhibitor and binding site were found, contrasting with previously published crystal structures of papaverine-like inhibitors. In accordance with the known antipsychotic potential of PDE10A inhibitors, MK-801 induced stereotypy and hyperactivity in rats were reversed by selected compounds. Thus, a promising compound class has been identified for the treatment of schizophrenia that could circumvent side effects connected with current therapies.
• PYRIDO[3,2-e]PYRAZINES, THEIR USE AS INHIBITORS OF PHOSPHODIESTERASE 10, AND PROCESSES FOR PREPARING THEM
  申请人：Elbion Gmbh

  公开号：EP2021342A1

  公开（公告）日：2009-02-11